What is the ROE (Return on Equity) of Fusion Antibodies this year?
The ROE of Fusion Antibodies this year is -2.31 undefined.
In 2024, Fusion Antibodies's return on equity (ROE) was -2.31, a 609.68% increase from the -0.33 ROE in the previous year.
Fusion Antibodies's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Analyzing Fusion Antibodies's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Fusion Antibodies's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Changes in Fusion Antibodies’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
The ROE of Fusion Antibodies this year is -2.31 undefined.
The ROE of Fusion Antibodies has increased by 609.68% increased compared to the previous year.
A high ROE indicates that Fusion Antibodies generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
A low ROE can indicate that Fusion Antibodies is having difficulties monetizing its investments successfully and can be a negative signal for investors.
A change in ROE (Return on Equity) of Fusion Antibodies can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Some factors that can influence Fusion Antibodies's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
Over the past 12 months, Fusion Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Antibodies is expected to pay a dividend of 0 GBP.
The current dividend yield of Fusion Antibodies is .
Fusion Antibodies pays a quarterly dividend. This is distributed in the months of .
Fusion Antibodies paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
Fusion Antibodies is assigned to the 'Health' sector.
To receive the latest dividend of Fusion Antibodies from 8/7/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/7/2024.
The last dividend was paid out on 8/7/2024.
In the year 2023, Fusion Antibodies distributed 0 GBP as dividends.
The dividends of Fusion Antibodies are distributed in GBP.
Our stock analysis for Fusion Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.